Horizon Scanning

It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.

The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:

  • Is this emerging technology new or replacing an existing technology?
  • Where is this technology in the FDA regulatory process?
  • When will this technology be commercially available in the market?
  • What is the projected use, cost, and financial impact of this technology?

NT-501 Encapsulated Cell Technology (ECT)

A retrievable intravitreal implant for continual long-term delivery of ciliary neurotrophic factor directly to the retina to treat early- and late-stage retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration.

Optimizer™ III System

An implantable device to deliver cardiac contractility modulation therapy to heart failure patients with medically refractory advanced symptoms.

Victrelis™ (Boceprevir)

An oral protease inhibitor for the treatment of hepatitis C virus genotype 1 infection among treatment-naïve and previously treated patients when added to current care combination therapies.